Literature DB >> 26339766

The mast cell as a pluripotent HDL-modifying effector in atherogenesis: from in vitro to in vivo significance.

Miriam Lee-Rueckert1, Petri T Kovanen.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize evidence about the effects that mast cell mediators can exert on the cholesterol efflux-inducing function of high density lipoproteins (HDL). RECENT
FINDINGS: Subendothelially located activated mast cells are present in inflamed tissue sites, in which macrophage foam cells are also present. Upon activation, mast cells degranulate and expel 2 major neutral proteases, chymase and tryptase, and the vasoactive compound histamine, all of which are bound to the heparin-proteoglycan matrix of the granules. In the extracellular fluid, the proteases remain heparin-bound and retain their activities, whereas histamine dissociates and diffuses away to reach the endothelium. The heparin-bound mast cell proteases avidly degrade lipid-poor HDL particles so preventing their ability to induce cholesterol efflux from macrophage foam cells. In contrast, histamine enhances the passage of circulating HDL through the vascular endothelium into interstitial fluids, so favoring HDL interaction with peripheral macrophage foam cells and accelerating initiation of macrophage-specific reverse cholesterol transport.
SUMMARY: Mast cells exert various modulatory effects on HDL function. In this novel tissue cholesterol-regulating function, the functional balance of histamine and proteases, and the relative quantities of HDL particles in the affected microenvironment ultimately dictate the outcome of the multiple mast cell effects on tissue cholesterol content.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26339766     DOI: 10.1097/MOL.0000000000000224

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  7 in total

1.  Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases.

Authors:  Shobini Jayaraman; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-18       Impact factor: 5.187

2.  Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr192 and compromises its cardioprotective activity.

Authors:  Ilona Kareinen; Marc Baumann; Su Duy Nguyen; Katariina Maaninka; Andrey Anisimov; Minoru Tozuka; Matti Jauhiainen; Miriam Lee-Rueckert; Petri T Kovanen
Journal:  J Lipid Res       Date:  2018-03-26       Impact factor: 5.922

3.  Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.

Authors:  Su Duy Nguyen; Katariina Maaninka; Jani Lappalainen; Katariina Nurmi; Jari Metso; Katariina Öörni; Mohamad Navab; Alan M Fogelman; Matti Jauhiainen; Miriam Lee-Rueckert; Petri T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

Review 4.  Inflammation in atherosclerotic cardiovascular disease.

Authors:  Prediman K Shah; Dalgisio Lecis
Journal:  F1000Res       Date:  2019-08-09

Review 5.  Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis.

Authors:  Martina B Lorey; Katariina Öörni; Petri T Kovanen
Journal:  Front Cardiovasc Med       Date:  2022-03-03

Review 6.  Immune system and atherosclerosis: Hostile or friendly relationship.

Authors:  Iman Razeghian-Jahromi; Ali Karimi Akhormeh; Mahboobeh Razmkhah; Mohammad Javad Zibaeenezhad
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

7.  Mast cells and acute coronary syndromes: relationship between serum tryptase, clinical outcome and severity of coronary artery disease.

Authors:  Nuccia Morici; Laura Farioli; Laura Michelina Losappio; Giulia Colombo; Michele Nichelatti; Donatella Preziosi; Gianluigi Micarelli; Fabrizio Oliva; Cristina Giannattasio; Silvio Klugmann; Elide Anna Pastorello
Journal:  Open Heart       Date:  2016-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.